Patent case between Mylan and Genzyme dismissed

A US district court has dismissed a patent infringement lawsuit between US-based biotechnology company Genzyme and Mylan Pharmaceuticals after the companies agreed to settle.

In September, Genzyme filed a complaint in the US District Court for the District of New Jersey against Mylan for allegedly infringing its patent covering the drug Clolar (clofarabine).

The patent involved is US number 5,661,136.

Clolar is a cancer treatment that interferes with the growth of cancer cells and slows the growth and spread of them in the body.

Genzyme filed suit after Mylan filed an Abbreviated New Drug Application with the Food and Drug Administration, seeking permission to bring a generic version of the drug to market.

Following the order of dismissal on Monday, November 28 by Judge Stanley Chesler, all claims and counterclaims have been dismissed.

Both parties will cover their own costs and attorneys’ fees, and they have waived any right to appeal.